All together these data support the hypothesis that primitive CP-CML cells are not dependent on BCL2 protein for their survival as the self-renewal reduction observed after BCL2 and BCR-ABL1 kinase inhibition was dependent only by Nilotinib exposure. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.